PTPRC and neoplasm: The latter two strategies significantly enhanced the number of tumor-infiltrating AII cells compared to intravenous administration in NOG mice, where the number of tumor-infiltrating CD45+ cells remained low (Fig. 2b-c, P< 0.05).